Participants 120 152 8
inguinal herniorrhaphy patients.
Participants 424 597 8
patients undergoing inguinal herniorrhaphy who receive a COX-2 selective nonsteroidal anti-inflammatory drug (COX-2) or placebo preoperatively and for 4 days postoperatively
Participants 685 759 7
adults undergoing elective, outpatient, unilateral inguinal herniorrhaphy.
Participants 1338 1450 7
Fifty-five subjects completed the study. Twenty-six patients received rofecoxib and 29 patients received placebo
Participants 2376 2409 4
outpatient inguinal hernia repair
